Synapse - Works

Results (399)

Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer

Journal Article

Lumish, M. A.; Walch, H.; Maron, S. B.; Chatila, W.; Kemel, Y.; Maio, A.; Ku, G. Y.; Ilson, D. H.; Won, E.; Li, J.; more...
JNCI: Journal of the National Cancer Institute (2024)

Fulltext@MSK | Save

Combined RAF and MEK inhibition to treat activated non-V600 BRAF-altered advanced cancers

Journal Article

Rustgi, N.; Maria, A.; Toumbacaris, N.; Zhao, H.; Kargus, K.; Bryant, M.; Waksmundzki, A.; Aricescu, I.; Lefkowitz, R. A.; Li, B. T.; more...
The Oncologist (2024)

Fulltext@MSK | Save

Efficacy of BRAF inhibitor plixorafenib (Fore8394) in recurrent, primary central nervous system tumors (PCNST)

Meeting Abstract

de la Fuente, M.; Butowski, N.; Taylor, J.; Yaeger, R.; Tsai, F. Y. C.; Janku, F.; Allen, C.; Ammakkanavar, N.; Michelson, G.; Jiang, P.; more...
Neuro-Oncology (2023)

Fulltext@MSK | Save

Genomic characteristics and clinical outcomes of stereotactic radiosurgery for colorectal cancer brain metastases

Meeting Abstract

Gui, C.; Walch, H.; Mueller, K.; Eichholz, J.; Khatri, I.; Del Balzo, L.; Kemeny, N.; Imber, B.; Schultz, N.; Foote, M.; more...
Neuro-Oncology (2023)

Fulltext@MSK | Save

Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2— , locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

Meeting Abstract

Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; van Cutsem, E.; Gallego Plazas, J.; Huang, J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Meeting Abstract

Oh, D. Y.; Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Omori, T.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

Meeting Abstract

Chan, S. L.; Sangro, B.; Kelley, R. K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E. N.; Furuse, J.; Kang, Y. K.; Galle, P. R.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

Meeting Abstract

Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup

Meeting Abstract

Yoshino, T.; André, T.; Kim, T. W.; Yong, W. P.; Shiu, K. K.; Vittrup Jensen, B.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer

Meeting Abstract

Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Stadler, Z.; Yaeger, R.; Smith, J. J.; Saltz, L.; Widmar, M.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save